Xuhui Bao

Dr. Xuhui Bao


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2024 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
XBXuhui Bao
Xuhui Bao
YLYongjun Liang
Yongjun Liang
HCHanman Chang
Hanman Chang
TCTianji Cai
Tianji Cai
BFBaijie Feng
Baijie Feng
LXLiyi Xie
Liyi Xie
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related cardiovascular diseases (CVD). This comprehensive review delineates the intricate roles and wide-ranging implications of PCSK9, extending beyond CVD to emphasize its significance in diverse physiological and pathological states, including liver diseases, infectious diseases, autoimmune disorders, and notably, cancer. Our exploration offers insights into the interaction between PCSK9 and low-density lipoprotein receptors (LDLRs), elucidating its substantial impact on cholesterol homeostasis and cardiovascular health. It also details the evolution of PCSK9-targeted therapies, translating foundational bench discoveries into bedside applications for optimized patient care. The advent and clinical approval of innovative PCSK9 inhibitory therapies (PCSK9-iTs), including three monoclonal antibodies (Evolocumab, Alirocumab, and Tafolecimab) and one small interfering RNA (siRNA, Inclisiran), have marked a significant breakthrough in cardiovascular medicine. These therapies have demonstrated unparalleled efficacy in mitigating hypercholesterolemia, reducing cardiovascular risks, and have showcased profound value in clinical applications, offering novel therapeutic avenues and a promising future in personalized medicine for cardiovascular disorders. Furthermore, emerging research, inclusive of our findings, unveils PCSK9’s potential role as a pivotal indicator for cancer prognosis and its prospective application as a transformative target for cancer treatment. This review also highlights PCSK9’s aberrant expression in various cancer forms, its association with cancer prognosis, and its crucial roles in carcinogenesis and cancer immunity. In conclusion, this synthesized review integrates existing knowledge and novel insights on PCSK9, providing a holistic perspective on its transformative impact in reshaping therapeutic paradigms across various disorders. It emphasizes the clinical value and effect of PCSK9-iT, underscoring its potential in advancing the landscape of biomedical research and its capabilities in heralding new eras in personalized medicine.

1 May 2024 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
XZXi Zheng
Xi Zheng
CZChenyang Zhang
Chenyang Zhang
TYTao Yang
Tao Yang
ZLZhanyang Luo
Zhanyang Luo
JXJunyi Xia
Junyi Xia
XBXuhui Bao
Xuhui Bao
Background: Hypertrophic cardiomyopathy (HCM), identified as a primary cause of sudden cardiac death (SCD), intertwines with pulmonary hypertension (PH) to amplify cardiovascular morbidity. This complex synergy poses significant therapeutic challenges due to the absence of drugs specifically targeting their concurrent manifestation. This study seeks to unravel the molecular intricacies linking HCM and PH, aiming to lay the groundwork for targeted therapeutic interventions. Methods: Through the analysis of gene expression profiles from datasets GSE36961 (HCM) and GSE113439 (PH) within the public data repository of Gene Expression Omnibus (GEO), this research systematically identified differentially expressed genes (DEGs), conducted extensive functional annotations, and constructed detailed protein-protein interaction (PPI) networks to uncover crucial hub genes. Further, co-expression analyses, alongside drug prediction and molecular docking simulations, were employed to pinpoint potential therapeutic agents that could ameliorate the combined pathology of HCM and PH. Results: Our comprehensive analysis unearthed 79 DEGs shared between HCM and PH, highlighting fourteen as pivotal hub genes. Validation across three additional datasets (GSE35229, GSE32453, and GSE53408) from GEO accentuated secreted phosphoprotein 1 (SPP1) as a key gene of interest. Remarkably, the study identified tacrolimus, ponatinib, bosutinib, dasatinib, doxorubicin, and zanubrutinib as promising drugs for addressing the dual challenge of HCM and PH. Conclusions: The findings of this investigation shed light on the genetic underpinnings of HCM and PH’s simultaneous occurrence, emphasizing the central role of SPP1 in their pathogenesis. The identification of six candidate drugs offers a hopeful vista for future therapeutic strategies targeting this complex cardiovascular interplay, marking a significant stride towards mitigating the compounded morbidity of HCM and PH. Future mechanistic and clinical studies are warranted for the investigation of this potential target and therapeutics.

23 July 2025 in Journal of Alzheimer's Disease Reports
Verified
Journal Article
Open access
WSWeidong Sun
Weidong Sun
AZAnlong Zhu
Anlong Zhu
HCHanman Chang
Hanman Chang
JXJunyi Xia
Junyi Xia
JGJun Gao
Jun Gao
XBXuhui Bao
Xuhui Bao
Background: There is increasing evidence suggesting a correlation between neurodegenerative diseases (NDDs) and constipation; however, their genetic relationship and causal mechanisms remain inadequately elucidated. Objective: We aim to investigate the causal link and shared genetic basis between NDDs and constipation. Methods: We obtained summary statistics from large-scale genome-wide association studies, encompassing five NDDs, including Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Lewy body dementia (LBD), as well as constipation. The primary analysis employed five Mendelian randomization methods to evaluate causal effects, while linkage disequilibrium score regression (LDSC) and high-definition likelihood (HDL) were utilized to investigate genetic correlations. Additionally, significant pleiotropic SNPs were identified using pleiotropic analysis under the composite null hypothesis (PLACO) and functional mapping and annotation (FUMA). Finally, enrichment analysis was conducted to explore the biological pathways associated with the identified pleiotropic genes. Results: MR analysis revealed a significant causal relationship between AD and an enhanced risk of constipation was demonstrated (OR = 1.043, 95% CI: 1.015–1.073, p = 0.003), while no causality was found between PD, MS, ALS, LBD, and the risk of constipation (p > 0.05). LDSC and HDL analysis revealed a significant positive genetic correlation between AD and constipation. Using PLACO combined with FUMA, we identified 30 overlapping pleiotropic loci, with pathway enrichment analysis revealing important biological pathways related to Aβ metabolism and processing, tau protein process, and the complement and coagulation cascades. Conclusions: Our study indicates that AD is a contributing factor to constipation and uncovers the complex genetic mechanisms linking AD and constipation, which holds significant implications for diagnosis and treatment of both conditions.

Verified
Journal Article
Open access
PDF file
EGElena Gantsova
Elena Gantsova
IAIrina Arutyunyan
Irina Arutyunyan
ASAnna Soboleva
Anna Soboleva
VMViktoriia Mikhailovskaia
Viktoriia Mikhailovskaia
EKEvgeniya Kananykhina
Evgeniya Kananykhina
Timur FatkhudinovTimur Fatkhudinov
Timur Fatkhudinov
Lung cancer is the most common type of cancer worldwide. Tumors carrying a mutation in the STK11 gene are associated with severe prognosis and resistance to therapy. New treatments for pulmonary adenocarcinoma highlight the efficacy of High-LET neutron therapy, often combined with drug therapy. PCSK9, whose inhibitors are used to treat dyslipidemia, may also be a new target in lung cancer therapy. CRISPR-Cas9-mediated STK11 mutation was performed in murine LLC1 lung adenocarcinoma cells. Human A549 cells that naturally carry a homozygous loss-of-function mutation in the STK11 gene were also used. Cells were irradiated with protons, neutrons, and photons (2 Gy) and analyzed for survival, apoptosis, clonogenic survival assay, and evolocumab (PCSK9 inhibitor) sensitivity. In vivo xenograft (Nude) and syngeneic (C57BL/6) subcutaneous tumor models were neutron-irradiated (5 Gy). Tumor cell proliferation, microenvironment, and protein expression were assessed. High-LET irradiation confirmed the STK11-deficient lines radio resistance, which did not reduce under PCSK9 inhibitor treatment conditions in vitro. In animal models, the PCSK9 inhibitor decreased Ki67 index of tumor cells and infiltration of cancer-associated fibroblasts and macrophages in the combination therapy group. Particle therapy resistance serves as a crucial prognostic marker in the management of lung adenocarcinoma. Using cell lines and animal models, we successfully described this resistance phenotype and demonstrated the promising use of a PCSK9 inhibitor to enhance the efficacy of hadron radiotherapy against lung cancer.

12 July 2026 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
ZZZong-Lei Zhou
Zong-Lei Zhou
LZLi-Gang Zhou
Li-Gang Zhou
CQChun-Hua Qu
Chun-Hua Qu
CFChun-Xiang Fan
Chun-Xiang Fan
HQHai-Hong Qu
Hai-Hong Qu
JLJiyu Li
Jiyu Li
Insulin resistance (IR) correlates with a wide spectrum of diseases and death. However, the specific proteomic signatures of IR and their associations with

9 July 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
TYTao Yang
Tao Yang
YLYi Lu
Yi Lu
YLYu-Qin Li
Yu-Qin Li
XBXuhui Bao
Xuhui Bao
HLHui Lu
Hui Lu
WXWujun Xiong
Wujun Xiong
Background: Hepatocellular carcinoma (HCC) is associated with poor prognosis and limited responses to immunotherapy, partly due to the immunosuppressive tumor microenvironment (TME). Tumor-associated macrophages, especially M2-like macrophages, play important roles in HCC progression. Interleukin-4-induced gene 1 (IL4I1), a tryptophan-metabolizing enzyme, has been implicated in tumor immune regulation. However, the role and prognostic significance of IL4I1-expressing M2-like macrophages in HCC remain unclear. This study investigated the expression pattern, spatial distribution, functional association, and prognostic relevance of IL4I1-expressing M2-like macrophages in HCC and their association with patient outcomes. Methods: We analyzed public databases (TIMER, UALCAN, TISCH2) for gene expression and prognostic significance. An in vitro co-culture system was established using a Huh7 HCC cell line and THP-1-derived M2-like macrophages with and without IL4I1 knockout via CRISPR/Cas9. We assessed cell proliferation, migration, apoptosis, and cytokine profiles. Multiplex immunofluorescence (mIF) was performed on tissue microarrays from 92 HCC patients to analyze the spatial distribution of IL4I1+ M2-like macrophages. Results: IL4I1 was highly expressed in HCC, predominantly within macrophages, and correlated with poor prognosis. In a THP-1-derived macrophage/Huh7 co-culture model, IL4I1 expression in M2-like macrophages was associated with increased Huh7 cell proliferation and migration and reduced apoptosis. This was associated with increased secretion of pro-inflammatory cytokines (e.g., CCL15, TNF-α) and decreased levels of IL-10 and TGF-β1. mIF analysis further showed that a high density of IL4I1+ M2-like macrophages in the epithelial/parenchymal tumor region was significantly associated with poorer overall survival ( p = 0.033). Conclusions: IL4I1+ M2-like macrophages are associated with a pro-tumorigenic microenvironment and adverse patient outcomes in HCC. Our findings support IL4I1+ M2-like macrophages as a prognostically relevant macrophage subset, while further mechanistic validation, particularly of IL4I1-derived metabolites and AHR pathway activation, is required before IL4I1 can be considered a validated therapeutic target.